• Explore /
  • Poster
  • / A phase Ib/II study of AK112, a PD-1/VEGF bispecific antibody, as first- or second-line therapy for advanced non–small cell lung cancer (NSCLC).

A phase Ib/II study of AK112, a PD-1/VEGF bispecific antibody, as first- or second-line therapy for advanced non–small cell lung cancer (NSCLC).

Abstract Poster

Authors

null

Caicun Zhou

Shanghai Pulmonary Hospital, Shanghai, China

Caicun Zhou , Shengxiang Ren , Yongzhong Luo , Lei Wang , Anwen Xiong , Chunxia Su , Zhihong Zhang , Wei Li , Jin Zhou , Xinmin Yu , Yanping Hu , Xiaodong Zhang , Xiaorong Dong , Xiaoming Hou , Yuanrong Dai , Weifeng Song , Baiyong Li , Zhongmin Maxwell Wang , Yu Xia

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lung Cancer—Non-Small Cell Metastatic

Track

Lung Cancer

Sub Track

Metastatic Non–Small Cell Lung Cancer

Clinical Trial Registration Number

NCT04900363

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 9040)

DOI

10.1200/JCO.2022.40.16_suppl.9040

Abstract #

9040

Poster Bd #

28

Abstract Disclosures

Similar Posters

First Author: Panpan Zhang

First Author: Qing Zhou

First Author: Chunjiao Wu

First Author: Antoine Italiano